SV2005002129A - NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360A - Google Patents

NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360A

Info

Publication number
SV2005002129A
SV2005002129A SV2005002129A SV2005002129A SV2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A
Authority
SV
El Salvador
Prior art keywords
sexual
disorder
disorders
compounds
dysfunction
Prior art date
Application number
SV2005002129A
Other languages
Spanish (es)
Inventor
Allerton Charlotte Moira Norfor
Andrew Simon Cook
David Hepworth
Duncan Charles Miller
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2005002129(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of SV2005002129A publication Critical patent/SV2005002129A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE FORMULA (I): (VER FORMULA) QUE SON UNA CLASE DE AGONISTAS DE DOPAMINA, MAS PARTICULARMENTE UNA CLASE DE AGONISTAS QUE SON SELECTIVOS PARA D3 SOBRE D2. ESTOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE LA DISFUNCION SEXUAL, POR EJEMPLO LA DISFUNCION SEXUAL FEMENINA (FSD), EN PARTICULAR EL TRASTORNO DE LA EXCITACION SEXUAL FEMENINA (FSAD), TRASTORNO DEL DESEO SEXUAL HIPOACTIVO (HSDD; FALTA DE INTERES EN EL SEXO), TRASTORNO ORGASMICO FEMENINO (FOD; INCAPACIADAD PARA ALCANZAR EL ORGASMO); Y LA DISFUNCION SEXUAL MASCULINA, EN PARTICULAR LA DISFUNCION ERECTIL MASCULINA (MED). LA DISFUNCION SEXUAL MASCULINA SEGUN SE REFIERE EN LA PRESENTE MEMORIA SE SUPONE QUE INCLUYE TRASTORNOS EYACULATORIO TALES COMO EYACULACION PRECOZ, ANORGASMIA (INCAPACIDAD PARA ALCANZAR EL ORGASMO) O TRASTORNOS DEL DESEO TALES COMO EL TRASTORNO DEL DESEO SEXUAL HIPOACTIVO (HSDD; FALTA DE INTERES EN EL SEXO). ESTOS COMPUESTOS TAMBIEN SON UTILES PARA TRATAR TRASTORNOS NEUROPSIQUIATRICOS Y TRASTORNOS NEURODEGENERATIVOSTHIS INVENTION PROVIDES FORMULA COMPOUNDS (I): (SEE FORMULA) THAT ARE A CLASS OF DOPAMINE AGONISTS, MORE PARTICULARLY A CLASS OF AGONISTS THAT ARE SELECTIVE FOR D3 ON D2. THESE COMPOUNDS ARE USEFUL FOR THE TREATMENT AND / OR PREVENTION OF SEXUAL DYSFUNCTION, FOR EXAMPLE THE FEMALE SEXUAL DYSFUNCTION (FSD), IN PARTICULATE THE FEMALE SEXUAL EXCITATION DISORDER (FSAD), THE HIPO-SEXUAL SEXUAL DESIRE DISORDER (HIPOACD); IN THE SEX), FEMALE ORGASMIC DISORDER (FOD; INABILITY TO REACH ORGASM); AND THE MALE SEXUAL DYSFUNCTION, IN PARTICULAR THE MALE ERECTILE DYSFUNCTION (MED). THE MALE SEXUAL DYSFUNCTION AS REFERRED TO IN THIS REPORT IS ASSUMED THAT IT INCLUDES EJACULATORY DISORDERS SUCH AS EFFECTIVE EJACULATION, ANORGASMIA (INABILITY TO ACHIEVE THE ORGASM) OR DISASTER DISORDERS OF SUCH AS THE DISORDER IN THE HALF; SEX). THESE COMPOUNDS ARE ALSO USEFUL TO TREAT NEUROPSYCHIATRIC DISORDERS AND NEURODEGENERATIVE DISORDERS

SV2005002129A 2004-05-27 2005-05-27 NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360A SV2005002129A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
SV2005002129A true SV2005002129A (en) 2005-12-13

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002129A SV2005002129A (en) 2004-05-27 2005-05-27 NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360A

Country Status (21)

Country Link
EP (1) EP1758862A1 (en)
JP (1) JP4198183B2 (en)
AP (1) AP2006003824A0 (en)
AR (1) AR049548A1 (en)
AU (1) AU2005247699A1 (en)
BR (1) BRPI0511571A (en)
CA (1) CA2567935C (en)
EA (1) EA200601982A1 (en)
EC (1) ECSP067029A (en)
GT (1) GT200500125A (en)
IL (1) IL179314A0 (en)
MA (1) MA28607B1 (en)
MX (1) MXPA06013786A (en)
NL (1) NL1029139C2 (en)
NO (1) NO20065326L (en)
PA (1) PA8635101A1 (en)
PE (1) PE20060366A1 (en)
SV (1) SV2005002129A (en)
TW (1) TW200609216A (en)
UY (1) UY28925A1 (en)
WO (1) WO2005115985A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) * 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
CA2752105C (en) 2009-02-13 2017-10-31 Matthias Vennemann Fused pyrimidines
MX357614B (en) * 2010-04-12 2018-07-17 Supernus Pharmaceuticals Inc Methods for producing viloxazine salts and novel polymorphs thereof.
EP2726171B1 (en) 2011-06-30 2017-05-17 Donaldson Company, Inc. Air/oil separator assemblies
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
HRP20211868T1 (en) 2016-07-20 2022-03-04 Novartis Ag Aminopyridine derivatives and their use as selective alk-2 inhibitors
WO2020210785A1 (en) * 2019-04-12 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
BR112022009710A2 (en) 2019-11-22 2022-08-09 Incyte Corp COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
AU2021292484A1 (en) 2020-06-16 2023-01-19 Incyte Corporation ALK2 inhibitors for the treatment of anemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
JP3889775B2 (en) * 2002-12-10 2007-03-07 ファイザー・インク I. A. Morpholine derivatives for use as dopamine agonists in the treatment of sexual dysfunction

Also Published As

Publication number Publication date
EP1758862A1 (en) 2007-03-07
IL179314A0 (en) 2007-03-08
MXPA06013786A (en) 2007-01-25
TW200609216A (en) 2006-03-16
JP4198183B2 (en) 2008-12-17
JP2008500331A (en) 2008-01-10
MA28607B1 (en) 2007-05-02
BRPI0511571A (en) 2008-01-02
NO20065326L (en) 2006-12-19
NL1029139C2 (en) 2006-06-19
AP2006003824A0 (en) 2006-12-31
AU2005247699A1 (en) 2005-12-08
PA8635101A1 (en) 2006-05-16
UY28925A1 (en) 2005-12-30
ECSP067029A (en) 2006-12-29
AR049548A1 (en) 2006-08-16
CA2567935C (en) 2009-10-27
PE20060366A1 (en) 2006-05-15
NL1029139A1 (en) 2005-11-30
CA2567935A1 (en) 2005-12-08
WO2005115985A1 (en) 2005-12-08
GT200500125A (en) 2006-01-10
EA200601982A1 (en) 2007-04-27

Similar Documents

Publication Publication Date Title
SV2005002129A (en) NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS REF. PC32360A
CL2017001426A1 (en) New compounds of 3-substituted 5-amino-6h-thiazolo [4,5-d] pyrimidin-2,7-dione for the treatment and prophylaxis of viral infections.
CL2017002150A1 (en) Chimeric anti-dll3 antigen receptors and methods of use
CL2017003404A1 (en) Antibacterial compounds
SV2016005257A (en) BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS
CL2016000341A1 (en) Methods to treat myositis by sporadic inclusion bodies
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
CL2015002675A1 (en) CFR mRNA compositions and related methods and uses
CO6430487A2 (en) ANTI-HER ANTIBODIES
PE20190973A1 (en) TETRAHYDROPIRAZOLOPIRIMIDINE COMPOUNDS
CL2017001718A1 (en) Glucagon derivatives with improved stability
CL2019003670A1 (en) Composition comprising mannose oligosaccharide and process to make it and use of it.
CO2019011546A2 (en) Compounds and methods for the treatment of parasitic diseases
SV2017005368A (en) [1,2,4] TRIAZOLO [4,3-B] PIRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
CR20150496A (en) NEW INHIBITING COMPOUNDS OF TYPE 10A PHOSPHODIESTERASE
CL2020001107A1 (en) Novel pyrazolo-pyrrolo-pyrimidine derivatives as p2x3 inhibitors.
AR072425A1 (en) USE OF NIFURTIMOX FOR THE TREATMENT OF GIARDIASIS
CU20150176A7 (en) DERIVATIVES OF SUPPLY OF SUBSTITUTED TRIAZOLPIRIDINES
CY1120178T1 (en) TREATMENT OF MENOPAUSAL EXTRACTS WITH ROPINIROL AND TIZANIDINE
BR112016000431A8 (en) compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
SV2005002128A (en) "NEW DERIVATIVES OF INDAZOL AND INDOLONA AND ITS USE AS PHARMACEUTICAL PRODUCTS" REF. PC32256A
CL2015003460A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for the treatment of an ophthalmic disease
AR100444A1 (en) USE OF PALMITOYLETHANOLAMIDE IN OPIOID COMBINATION
DOP2005000095A (en) NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS
DOP2005000093A (en) NEW DERIVATIVES OF INDAZOL AND INDOLONA AND ITS USE AS PHARMACEUTICAL PRODUCTS

Legal Events

Date Code Title Description
FD Lapse